Orchestra BioMed Holdings Inc (OBIO) — Titan Protect Analysis

OBIO

Orchestra BioMed Holdings Inc

Healthcare · ·

$3.90

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$233M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.67

Based on estimated future earnings — lower means cheaper

Rev Growth

-87.3%

Year-over-year revenue change

Profit Margin

-167.0%

How much profit the company keeps from each dollar of revenue

ROE

-161.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+156% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 6 analysts covering this stock

About Orchestra BioMed Holdings Inc

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications,

https://www.orchestrabiomed.com

Country: United States Employees: 86 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.018

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0203

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.399

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-29.1%

Historical annualised return based on price data

Max Drawdown

-72.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

136

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$5.42

28% below the year high

52W Low

$2.20

77% above the year low

Avg Volume

209,663

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.95

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

31.10

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

99.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-20,069.1%

Profit from core operations before interest and tax

Free Cash Flow

$-25,953,624

Negative — the business is spending more than it generates

Revenue (TTM)

$33M

Total revenue over the last 12 months

Net Income

$-54,926,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$20.00

Target Median

$10.00

Target Low

$9.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go